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Inhibition of Prothrombinose by Antithrombin-Heporin
of o Mocroscopic Surfoce
Hon Speijer, Didier Billy., George Willems, H, Coenrood Hemkel Theo Lindhout
From the Deportment of Biochemistry, Cordiovosculor Reseorch Institute Moostricht, Universiiy of Limburg,
Moosiricht, The Netherlonds
Summory
The antithrombin-dependent inhibition of prothrombinase, assemb-
led at a macroscopic surface, was studied under flow conditions utili-
zing a tubular flow reactor that consists of a phospholipid-coated glass
capillary. Prothrombinase activity was determined from steady-state
rates of thrombin production upon perfusion with protluombin and
from factor Va-associated factor Xa activity present in the flow reactor.
The prothrombinase density was maintained at a low level (0.03
fmol/cm2) to assure that the rate of thrombin production reflected the
amount of prothrombinase present in the capillary. Perfusion of the
flow reactor with antithrombin resulted in an exponential decrease of
prothrombinase activity in time. The second order rate constant (8.5 x
104 M-rmin-r) is comparable with the rate of inactivation of free factor
Xa. Inhibition was much faster when antithrombin was complexed with
heparin. The second order rate constants of inhibition decreased with
decreasing heparin chain length: 9.6 x 107, 4.5 x 107 and 0.39 x 107
M-rmin-r for unfractionated heparin, low molecular weight heparin and
synthetic pentasaccharide heparin, respectively. In the presence of pro-
thrombin (0.2 pM), however, the heparin-dependent rate of inhibition
of prothrombinase was about 5O-fold lower. The heparin-independent
inhibition of prothrombinase by antithrombin (4 pM) in the presence of
prothrombin (0.2 p,M) was virtually negligible. At a 70-fold higher sur-
face density of prothrombinase (2 fmol/cm2) prothrombinase activity
was much faster inactivated. The rate of thrombin production, however,
was not affected. In conclusion, at low prothrombinase d nsities, pro-
thrombin efficiently protects prothrombinase from inhibition. At high
densities, prothrombinase is much less protected but the higher ate of
prothrombinase inactivation has no consequences for the thrombin pro-
duction because of the transport-limited regime.
lnlroduclion
Upon vessel wall damage, blood coagulation is triggered, leading to
a number of proteolytic reactions which finally result in the formation
of fibrin. One of the central reactions in the cascade of coagulation
reactions i  the factor Xa-calalyzed activation of protluombin. The rate
of this thrombin-forming reaction is enhanced dramatically by the non-
enzymatic ofactor factor Va, calcium ions and phospholipid surfaces
(1-3). In vivo, the phospholipid surface is thought to be provided by
activated blood platelets or damaged cells present at the site of injury
(4-6). In this way propagation ofblood coagulation may be restricted to
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the region of the damaged vessel wall. Termination of the process of
thrombin generation is thought o be caused by the thrombin-mediated
elimination of the cofactors Va and VIIIa (7) and by the inactivation of
the serine proteases factor Xa and thrombin by the plasma inhibitor an-
tithrombin (8, 9). The latter reactions are dramatically enhanced by he-
parin (10-13), awidely used anticoagulant drug. Yet, inhibition ofclot-
bound thrombin and factor Xa are hardly affected by heparin (14-16).
A number of studies have demonstrated that phospholipids and
factor Va protect factor Xa from inhibition by antithrombin-heparin
(11-23). This protection was even more pronounced when the reaction
was studied in a tubular flow reactor (24). Recent work from our labo-
ratory (25) has indicated that the catalytic efficiency ofprothrombinase
in a tubular flow reactor is about two orders of magnitude higher than
in a vesicle system. Consequently, inhibition of prothrombinase in a
tubular flow reactor could be subject to protection by substrate compe-
tition. On the other hand, however, it has also to be expected that
because of the extremely high catalytic efficiency of prothrombinase at
a macroscopic surface, prothrombin activation can become easily
diffusion-controlled (25). Prothrombin concentrations ear the catalytic
surface then fall to values below the K, value and protection by
prothrombin will be abolished.
In this report, we present the results of a kinetic study on the inhibi-
tion of prothrombinase by antithrombin and heparin in a tubular flow
reactor. Using different enzyme surface densities, we studied inhibition
under conditions where the catalytic activity of prothrombinase ts the
pace and under conditions where transport of protluombin to the cata-
lytic surface limits the reaction rate. As long as thrombin formation was
not significantly limited by the transpofi rate ofprothrombin, o inhibi-
tion of prothrombinase by plasma concentrations of antithrombin was
observed. Only in the presence of heparin significant inhibition of
thrombin generation was found.
Expelimenlol Procedures
Materials. 52238, chromogenic substrate for thrombin, was obtained from
Chromogenix (Mrilndal, Sweden). Bovine serum albumin (fatty acid-free), gg
phosphatidylcholine (PC)and brain phosphatidylserine (PS)were from Sigma
(St. Louis, USA). Glass capillaries with a length of 127 mm and an intemal
diameter of 0.65 mm (42 p1 volume) were obtained from Brand AG (Wefiheim,
Germany). The 4th International Standard for Heparin (UFH) was a gift from
the National Institute for Biological Standards and Control (Potters Bar, UK)
Its potency was stated as 193 I U per mg. The low molecular weight heparin
(LMWH), enoxaparin (98 anti-Xa IU/mg), was obtained from Rh6ne-Poulenc
Rorer, France. The synthetic pentasaccharide heparin (1140 anti-Xa IU/mg)
was from the Choay Institute (Paris, France) The molar concentrations f
heparin species with high affiniqr for antittirombin were determined in each of
the preparations by stoichiometric titration of antitlrombln (26). The molar
amounts of antittrombin high affinity material in 1 g of UFH, LMWH and
pentasaccharide were 35 ;-r,mol, 29 pmol and 470 p,mol, respectively. Bovine
factor Va, human prothrombin, human factor Xa and human antithrombin were
purified and quantified as described (23,27).
Flow reactor. The preparation of phospholipid-coated capillaries and the
flow system were as described previously (25). Briefly, the capillary (0.65 mm
internal diameter and 127 mm length) was filled with a suspension ofunilamel-
lar phospholipid vesicles compose d of 75 mol%o egg phosphatidylcholine and
25 mol% brain phosphatidylserine in 50 mM Tris-HCl, 175 mM NaCl,
pH 7 9. After 20 min ofincubation with the 1 mM phospholipid suspension, the
capillary was rinsed with Tris-buffer (50 mM Tris-HCl, 175 mM NaCl,
0 5 mg/ml bovine serum albumin, pH 7.9) containing 3 mM CaCl, at a flow
rate of 1.2 mUmin for 2 min to remove non-bbund phospholipid. The phospho-
lipid-coated capillary was attached to a Hamilton gas-tight syringe. The flow
was controlled by a syringe pump (Harvard Apparatus Co., South Natick,
Massachusetts, USA). An XYZ translation table (Isel AG, Eiterfelt, Germany)
was used to collect samples (typically 30 pl) from the tip of the flow reactor
into disposable cuvettes (Sarstedt, Niimbrecht, Germany) containing 20 mM
EDTA in Tris-buffer. Thrombin was measured in the cuvette after the addition
of the chromogenic substrate 52238. All procedures were performed at 37o C
Inhibition of prothrombinase activity. The phospholipid-coated capillaries
were perfused with a mixture of factor Xa and factor Va (2 nM) for 10 min at
30 pUmin (shear ate ^0 s-r) to bind a fixed amount of prothrombinase The
factor Xa concentration in the perfusion mixture was var.ied to obtain
prothrombinase urface densities of about 0.03 and 2 fmol/cm2 The thrombin
production was measured by perfusion of the capillaries with factor Va (2 nM)
and prothrombin (200 nM). Samples (30 pl) of the effluenr were collected
every minute into cuvettes containing 500 pl Tris-buffer containing 20 mM
EDTA. After addition of 60 pl chromogenic substrare 52238 (2.5 mM) throm-
bin was measured as described (25). Inhibition ofprothrombinase was studied
by perfusion with a mixture containing factor Va (2 nM) and varying amounts
of antithrombin or antithrombin-heparin, either in the absence or presence of
200 nM prothrombin.
Determination of factor Xa activity bound to the swface of the phospho-
lipid-coated capillarjes. The residual factor Xa activity bound to the phospho-
lipid bilayer was determined at the end of an inhibition expenment The capil-
laries were washed for 5 min at 30 pl/min with Tris buffer (50 mM Tris-HCl,
175 mM NaCl, 3 mM CaCl, and 0.5 mg BSA/ml, pH 7.9) to remove thrombin
and were subsequently perfused for 5 min at 30 u,l/min with a Tris-EDTA
buffer (50 mM Tris, 175 mM NaCl, 5 mM EDTA, 0.5 mg/ml BSA) to remove
all bound factor Xa. The factor Xa activity present in the effluent was
determined via a bioassay as described (25)
EJJbct of transport limit on the kinetics of prothrombin activation
in the JIow reactor. Thrombin generation by prothrombinase bound to macro-
scopic surfaces easily becomes limited by the transfer of prothrombin from bulk
solution to the catalytic surface Efficient conversion of the prothrombin at the
surface results in depletion of the protein in the solution near the surface. The
transport of protein to the wall of the tubular flow reactor, J (pmol/min), is
proporlional to the difference between the protein concentration Co (pmol/ml)
in the bulk solution and Co (pmoVml), the protein concentration near the capil-
lary wall (28):
J = A (Cu-C") t1l
with the transport coefficient A (cm3/min) as a function of the geometry of the
capillary, the volumetric flow rate, the kinematic viscosity of the fluid and the
diffusion coefficient of the protein. For the flow rate of 30 pl/min and the
capillary (length 12.7 cm and inner diameter of 0.065 cm) used in this study, the
transport coefficient for prothrombin equals 0.0i08 cm3/min (25).
The resulting tkombin production is further determined by the intrinsic
conversion kinetics J,nn (pmol/min) which depends on the concentration of
prothrombin (C") at the capillary wall, on the amount ofprothrombinase bound
to the phospholipid bilayer in the capillary (E), the tumover number of the
enzyme ((",) and the Michaelis constant (Km):
J,n,. = k.u, E Co/(K.+ Co) t2l
In a previous tudy (25) we showed that equations 1-2 allow an adequate
description of observed protlrombin conversion kinetics with values
k*, = 3600 minr and K. = J n14
Resulls
Inhibition of Prothrombin Activation by Antithrombin
Phospholipid-coated capillaries were perfused with factor Xa (1 pM)
and factor Va (2 nM) for 10 mrn at 30 pl/min. These capillaries were
then perfused with prothrombin (0.2 pM) and factor Va (2 nM). The
average steady state thrombin concenffation atthe outlet was 12 + 0.2
nM (n = 5) and resulted from a steady state rate of thrombin production
at the wall of the capillary of about 0.36 pmol/min. This steady state
rate 0f thrombin production is well below the transport limiI, L.Cb=2.2
pmol/min (see Experimental Procedures). We previously demonstrated
that under these conditions thrombin production is proportional to the
prothrombinase activity (25). The prothrombinase concentratron as
measured from the amount of factor Xa bound to the phospholipid sur-
face in the tubular flow reactor was 0.09 t 0.01 fmol (mean + SD,
n = 5). As shown in Fig. 1, pedusion with prothrombin (0.2 plM) and
factor Va (2 nM) resulted after 7 min in a stable level of thrombin for-
mation. When perfusion was continued with a mixture containing pro-
thrombin (0.2 p,M), factor Va (2 nM) and antithrombin (2 pM), throm-
bin levels at the outlet of the capillary decreased. The disappearance of
the amidolytic activity was due to neuiralization of formed thrombin by
antithrombin. We emphasize that the absence of thrombin activity at
the outlet of the capillary because of inactivation by antithrombin
during its residence time of more than 1 min in the capillary does not
necessarily mean that the level of active thrombin is reduced at the site
of its production. Continuation of the perfusion with prothrombin
(0.2 p,M) and factor Va (2 nM) resulted in the same thrombin level as
before the inhibrtion step. Perfusion of the capillary at the end of the
experiment with EDTA and determination of factor Xa activity in the
effluent demonstrated the same molar concenffation of factor Xa
(0.034 frnol factor Xalcm2) as in an unffeated capillary (0.037 fmol fac-
tor Xalcm2). Increasing the antithrombin concentration i  the inhibitory
perfusion step to 4 pM did not affect he thrombin generating capacity,
nor the amount of factor Xa (0.034 fmol factor Xalcm2) bound to the
phosphoiipid layer in the capillary. These results thus indicate that pro-
thrombinase inhibition during prothrombin activation by antithrombin
is negligible small.
However, when prothrombin was omitted from the perfusion mix-
ture during the perfusion with factor Va and antithrombin, we found
that upon perfusion with 2 and 4 pM antithrombin the factor Xa
activity in the capillaries decreased from 0.037 fmol factor Xa/cm2 to
0.020 fmol factor Xa,/cm2 and 0.012 fmol factor Xa/cm2, respectively;
These values paralleled the reduction of the thrombin activity at the
outlet of the capillary Gig. 1). Fig.2 summarizes the residual prothrom-
binase activities as assessed from the steady state of thrombin produc-
tion and factor Xa measurements, after perfusion with varying amounts
of antithrombin either in the absence or presence of 0.2 p,M prothrom-
bin. It is clearly shown that during protluombin activation, prothrom-
binase bound at the phospholipid surface in the flow reactor was
virtually insensitive to inhibition by antithrombin. In the absence of
prothrombin, prothrombinase inactivation by antithrombin is much
faster and increased with the antithrombin concentration.
In order to obtain quantitative data on prothrombinase inhibition in
the flow reactor, inhibition by antithrombin in the absence of pro-
thrombin was measured as function of the perfusion time with inhibitor.
Capillaries containing prothrombinase at a sudace density of 0.022
fmol/cm2 were perfused with antithrombin (0.5 pM) and factor Va
(2 nM) for different ime periods. The extent of inhibition of prothrom-
binase was assessed from the factor Xa activity that was eluted from the
capillaries with EDTA. As expected for pseudo-first order kinetics a li-
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Fig. ) Inhibition of prothrombinase byantithrombin. Prothrombinase-contai-
ning capillaries were prepared by perfusing phospholipid-coated capillaries
with 1 pM factor Xa and 2 nM factor Va for 10 min, Prothrombinase d nsitres
were 0.037 fmol/cm2, Then thrombin production was started by pertusion with
prothrombin (0 2 pM) and factor Va (2 nM). After 16 min the perfusion
mixture was changed to a mixture containing 2 nM factor Va and (A), 2 pM
antithrombin and 0 2 pM prothrombin; (O), a pM antithrombin and 0 2 pM
prothrombin; (A), 2 pM antithrombin; or (O), 4 ptM antithrombin After
24 min the perfusion was continued with prothrombin (0.2 ptM) and factor Va
(2 nM) Thrombin concentrations at the outlet are ploned versus the perfusion
time Flow rate was 30 ul/min with a wall shear ate of 20 s-r
0 1 2 3
Antithrombin, pM
FiB.2 Effect of antithrombin concentration on prothrombinase inhibition,
Prothrombinase-containing capillaries were prepared as described in the legend
to Fig 1 To assess the inhibition of prothrombinase by antithrombin i  the ab-
sence ofprothrombin, the capillaries were lirst rinsed by a 5-min perfusion with
factor Va (2 nM), followed by 8 min perfusion with antithrombin and factor Va
(2 nM) Then the capillaries were rinsed again with factor Va (2 nM) and per-
centage of residual prothrombinase activity (O), was determined as bound fac-
tor Xa activity (see Experimental Procedures) Inhibition of prothrombinase by
varying antithrombin concentrations was also examined uring prothrombin
activation. Resrdual prothrombinase activities (O) were determined by compa-
ring the steady state of thrombin production before and after an 8-min perfusion
with antithrombin , prothrombin (0 2 pM) and factor Va (2 nM), Alternatively,
inhibition of prothrombinase in these capillaries was also assessed from the
amount of factor Xa activity rhat could be eluted with Tris-EDTA (I) Wall
shear ate was 20 s-r
near relationship was found between the logarithm ofresidual factor Xa
activity and the perfusion time (data not shown). A replot of the pseudo
first order rate constant of inhibition versus the antithrombin concen-
tration (Fig. 3) yields a second ordsr rate constant of prothrombinase
inhibitron of 0.85 x 10s M-l min r.
For prothrombinase inactivation during prothiombin activation the
extent of inhibition was too small to allow estimation of this rate
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constant with acceptable accuracy. Only a upper limit can be given ln
the presence of 0.2 pM prothrombin the second order ate constant 0f
prothrombinase inhibition is less than 2 x 103 M rmin-l.
I nhibiti on of P r o thr o mb in Ac t iv ati on by Antithr omb in/H e p a r i n
In simiizLr experiments as described before for antithrombin alone,
we perfused capillaries containing prothrombinase (0.035 fmol/cm2;
with prothrombin (0 2 pM) and factor Va (2 nM) to establish the
initial prothrombinase activity of the capillary. Subsequently, anti-
thrombin (0 5 p.M) and varying concenfations of heparin were
included in the perfusion mixture for 8 min. Residual prothrombinase
activity was measured by continuation of the perfusion with prothrom-
bin and factor Va after the inhibition step. At the end of each experi-
ment he capillaries were perfused with EDTA to determine the amount
of residual factor Xa activity. We verified, as described for antithrom-
bin a1one, that the inhibitory reaction followed pseudo-first order
kinetics. Fig 4 shows the rate constant of rnhibition as a function of the
heparin concentration. The heparins tudied were unfractionated hepa-
rin (UFH), the low molecular weight heparin (LMWH) enoxaparin and
the synthetic heparin pentasaccharide which contains the antithrombin
binding site. Because the antithrombin concentration (0.5 pM1 was far
above the reported issociation constant of the heparin-antithrombin
complexes (10 nM), we assumed that all antithrombin high affinity
heparins were complexed with antithrombin (26, 29). Indeed, the rate
constant of the UFH catalyzed reaction increased linearly wrth the
heparin concenffation up to 3 pr.g/ml (100 nM antithrombin high
affinity material). The inhibitory activity of the LMWH expreqsed per
mol of antithrombin high affinity material was about half that of UFH.
Interestingly, no further increase in the rate constant was seen with
pentasaccharide above I pg/ml. This amount 0f pentasaccharide
conesponds to a molar concentration f 0.5 pM and above this
concentration all antithrombin (0.5 pM) is saturated with the synthetic
heparin.
The second order rate constants of inhibition of prothrombinase
were calculated from the initial slopes of the plots as shown in Fig. 4
using the molar concentration of heparin as determined by stoichio-
metric titration with a known amount of antithrombin We found that
the rate constant for the inhibition reaction between prothrombinase
and antithrombin-UFH, either in the absence 0r presence of 0.2 pM
prothrombin, was about 30-fo1d higher than the rate constant ofthe in-
hibition reaction with antithrombin-pentasaccharide (Table I ).
Table I Second-order rate constants fbr the reactions of antithrombin or an-
tithronbin-heparin with prothrombin
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Flg. 3 Rate constant ofprothrombinase inhibition as a function of the anti-
thrombin concentration. Prothrombinase-containing cap llaries were prepared
as described in the legend to Fig. 1. Pseudo-first order ate constants of
prothrombinase inhibltion by antithrombin in the absence of prothrombin were
calculated from the data in Fig. 2. Further details are described in the text
P rothrombinas e Inhibition Durins. Transp ort Limited P rothrombin
Activation
We next examined the inhibition of prothrombinase by antithrom-
bin/heparin under conditions where thrombin production was iimited
by the transport of prothrombin to the catalytic surface. To this end, the
amount of prothrombinase in the capillary was increased from 0.09 to
5.2 fmol prothrombinase. With this surface density of prothrombinase
the intrinsic rate of thrombin production amounts k..,.[prothrombinase]
= 18.7 pmol/min, which is about 9-fold higher than the transport limit
at a prothrombin concentration f 0 2 U.M: J = 2.2 pmol/min (see
Experimental Procedures). After assembly of prothrombinase, the
thrombin production of the capillary was measured uring perfusion
with factor Va (2 nM) and prothrombin (0.2 pM). Next, the capillary
was perfused with 0.5 p.M antithrombin and heparin concentrations a
indicated in Fig.5. Finally, the remaining prothrombinase activity was
assessed bydetermination of the thrombin production during perfusion
o25
020
0 1 5
0 1 0
0 0 5
0  0 5  1 0  ' 1  5  2 0  2 5  3 0
Heparin, pg/ml
Flg. 4 Rate constant of prothrombinase inhibition as a function of the anti-
thrombin/heparin concentration. Prothrombinase-contarning capillaries were
prepared as described in the iegend to Fig 1 Pseudo-first order rate constants
of prothrombinase inhibition by antrthrombin in the presence of varying
amounts of UFH (O), LMWH (I) and pentasaccharide (A) were calculated as
described in the text
Heparin pg/ml
Flg 5 Inhibition of prothrombinase by antithrombin-UFH under transport-
Iimited conditions ofprothrombin activation Capillaries containing 5 2 fmol
prothrombinase were prepared by perfusing phospholipid-coated capillaries
with 01 nM factor Xa and 2 nM factor Va for l0 min at a wall sheu rate of
20 s1. The capillaries were then perfused for 8 min with 0.5 pM antithrombin
and UFH at the indicated concentrations and with a wall shear rate of 20 s I The
resrdual prothrombinase ctivity was assessed as escribed in the text. Symbols
indicate: (O), thrombin production expressed as percentage of the uninhibited
steady state thrombin production a d (A), remaining factor Xa activity bound
to the capillary as a percentage of factor Xa activity bound to the uninhibited
capillaries
with prothrombin (0.2 pM) and factor Va (2 nM). At the end of the
experiment the amount ofnon-inhibited prothrombinase in the capillary
was determined. Fig.5 shows that under these conditions the inhibition
of prothrombinase in the flow reactor had almost no effect on thrombin
generation. It is evident hat more than 8070 of theprothrombinase had
to be inactivated to decrease the rate of thrombin production below
the mass transfer ate of prothrombin This is consistent with our
theoretical analysis that the initial amount of prothrombinase was
9-fo1d the amount at which prothrombin activation becomes ftansport
limited. Half-maximal decrease of prothrombinase was found with
0.14 p,g/ml UFH, which equals 5 nM of heparin species with high
affinity for antithrombin. It is apparent that in the diffusion-controlled
situation, when prothrombinase is only partrally saturated with pro-
thrombin, factor Xa is much less protected from inhibition by anti-
thrombin/ heparin. Interestingly, at heparin concentrations higher
than 0.2 pg/ml the rate of inhibition of prothrombinase iowed down.
It is apparent that sufficient prothrombinase was inactivated to enter
a kinetically-controlled situation. That is, the rate of thrombin produc-
tion became lower than the rate of prothrombin transport o the
surface and ful1 protection of prothrombinase by prothrombin is then
feasible.
Discussion
We studied the inhibition by antithrombin-heparin of thrombin pro-
duction in a tubular flow reactor containing prothrombinase assembled
on a macroscopic phospholipid sudace. It is demonstrated that under
experimental conditions where thrombin production is proportional
with the surface density ofprothrombinase, antithrombin isa very poor
inhibitor of prothrombinase during prothrombin activation. Even at a
concenffation of antithrombin that exceeds the plasma concentration
and a prothrombin concentration that is only one{enth of the plasma
concentration, i hibition of prothrombinase after an 8 min perfusion is
almost negligible. The rate constant of inhibition by antithrombin was
c
E
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o
o
o
o
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estimated to be lower than 2 x 103 M I min 1. We showed that this
protection from inhibition is caused to a large extent 0 the presence of
prothrombin, because in the absence of prothrombin we measured a
much higher second order ate constant of antithrombin-dependent pro-
thrombinase inhibition (0.85 x 105 M-r min-r). This rate constant is
somewhat lower than the reported rate constant of factor Xa inhibition
of I.2x 10s M lmin I (30). Unfortunately, inhibition studies on factor
Xa bound to the phospholipid layer in the flow reactor could not be per-
formed because factor Xa readily dissociates from the surface in the
absence of factor Va (25). Thus, we could not establish whether the
interaction between factor Va and factor Xa at the phospholipid surface
also contributes to the protecting effect on factor Xa inactivation. An
alternative xplanation for the observed protection could be that anti-
thrombin ear the surface becomes neutralized by locaily high concen-
trations of thrombin(24). However, at an antithrombin concentration f
0.5 pM the maximal mass transfer equals 5.5 pmol/min (equation 1)
which is more than l0-fold higher than the thrombin production of
0.4 pmol/min at the surface. This makes that depietion of antithrombin
near the surface is highly un1ikely.
Heparin, in the absence of prothrombin, caused asignificant accele-
ration of prothrombinase-antithrombin reaction at the macroscopic sur-
face. Rate constants of inactivation were proportional with the heparin
concentration, indicating a second order reaction of prothrombinase
with heparin-antithrombin complexes. The second order rate constant
for the reaction between prothrombinase and antithrombin-UFH
heparin, antithrombin-LMWH and antithrombin-pentasaccharide com-
plexes were 9.6 x 107 M lmin-l, 4.5 x101 M-r min-r and 0.39 x 107 M I
min r, respectively. It is of interest t0 see that the anti-prothrombinase
activity of heparin decreased with decreasing heparin chain length. We
examined whether this difference between pentasaccharide and un-
fractionated heparin was the result of an antithrombin-independent
effect of the heparins on prothrombinase activity and found that the
steady-state rate of thrombin production was not affected by heparin in
the absence of antithrombin (data not shown). Earlier studies (3 1 ) ftom
our laboratory with factor Xa in the presence of Ca2*, but in the
absence of factor Va and phospholipids revealed about the same
differences, namely rate constants of 2 x 108 M-1 min l and 2 x 10? M 1
min-l for UFH- and pentasaccharide-antithrombin complexes,
respectively.
As demonstrated for the heparin-independent inhibition reaction,
protluombin protects prothrombinase also in the heparin-stimulated
inhibition reaction. The second order rate constants of inhibition for
UFH andpentasaccharide in the presence 0f0.2 pM prothrombin were
about 50-fo1d lower compared to those in the absence of prothrombin
(Table 1). The difference in anti-prothrombinase ctivity between UFH
and pentasaccharide repofied here for prothrombinase bound to a
macroscopic phospholipid surface during prothrombin activation
appears to be of the same magnitude (30-fold) as found for prothrom-
binase in the absence ofprothrombin. At present we have no explana-
tion for this marked difference in anti-prothrombinase activity. How-
ever, our findings suggest a role for heparin-prothrombinase int r-
actions, in addition t0 the pentasaccharide-induced antithrombin
conformational change, as contributors to heparin acceleration of the
antithrombin protluombinase r acti0n (30).
We have also performed inhibition studies under conditions where
the rate of thrombin production was limited by the supply of pro-
thrombin towards the catalytic surface. In such a situation prothrom-
binase is then only partially saturated with prothrombin. This, in turn,
makes that prothrombinase is more susceptible to inhibition by anti-
thrombin-heparin. I terestingly, in spite of an increased inactivation of
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prothrombinase, the rate of thrombin production remained unchanged
(Fig. 5). The rate of thrombin production will only stafi t0 decrease
when the activity of prothrombinase at the wall of the flow reactor
decreases below the level that causes transport-limited catalysis. Once
this situation is reached, however, prothrombin is not longer depleted
near the surface and again fully protects prothrombinase from
inhibition.
Collectively, our observations suggest that thrombin formation by
prothrombinase at a macroscopic surface such as thrombi can hardly be
regulated by heparin-antithrombin complexes for two reasons: i) when
prothrombinase is saturated with its substrate prothronbin, high
concentrations of heparin are needed to cope with the protective ffect
of prothrombin and ii) when prothrombinase activity is limited by the
supply of prothrombin, prothrombinase is readily inactivated by
heparin-antithrombin complexes but thrombin formation remains
unaffected.
D ^ 4 ^ . ^ ^ ^ ^ ^
I \ U I U I U I  I U V J
l.Hemker HC, Esnouf MP, Hemker PW, Swart ACW, MacFarldne RG
Formatlon of prothrombin convertlng activity Nature 1967 ; 215: 248-51.
2 Nesheim ME, Taswell JB, Mann KG. The contribution of bovine factor V
and factor Va to the activity of prothrombinase J Biol Chem 1979;254:
10952-62.
3 Rosing J, Tans G, Govers-Riemslag JWP, Zwaal RFA, Hemker HC The
role of phospholipids and factor Va in the prothrombinase complex. JBiol
Chem I 980; 255 27 4-283.
4. Rosing J, van Rijn JLML, Bevers EM, van Dieijen G, Comfurius P,Zwaal
RFA. The role of activated human platelets in prothrombin and factor X
activation. Blood 19901 65t 319-3t2.
5 Mann KG, Nesheim ME, Church WR, Haley P, Krishnaswamy S.Surface-
dependent reactions of the vitamin K-dependent enzyme complexes. Blood
1990:76 :  1 -16
6 Zwaal RFA, Comfurius P, Bevers EM. Platelet procoagulant activity and
microvesicle formation - its putative role in hemostasis and thrombosis
Biochim Biophys Acta 1992; I I 80: 1-8
7. Esmon CT. The roles of protein C and thrombomodulin i  the regulation of
blood coagulation JBiol Chem 1989;264:4143-6
8. Egeberg O. Inhereted antithrombin deficiency causing thrombophilia.
Thromb Diath Haemonh 1965: 13: 516-30.
9. Abildgaard U. Binding of thrombin to antithrombin III Scand J Clin Lab
1969;24:23-7
10. Rosenberg RD, Damus PS. The purification and mechanism of action of
human antithrombin-heparin cofactor. JBiol Chem I9'13: 248: 6490-505.
1 l. Danielsson A, Raub E, Lindahl U, Bjdrk I. Role of ternary complexes, in
which heparin binds both antithrombin and proteinase, in the acceleration
of the reactions between antithrombin and thrombin or factor Xa. J Biol
Chem 1986; 261.: 15467 -7 3
12. Olson ST. Transient kinetics of heparin-catalyzed protease inactivation by
antithrombin III Linkage of protease-inhibitor-heparin interactions in the
reaction with thombin. J Biol Chem 1988; 263:1698-708.
13. Craig PA, Olson ST, Shore JD. Transient kinetics of heparin-catalyzed
protease inactivation by antithrombin III Characterization f assembly,
product formation, and heparin dissociation steps in the factor Xa reaction.
J Biol Chem 1989 264:5452-61.
14 Hogg PJ, Jackson CM. Fibrin monomer protects thrombin from inactrvation
by heparin-antithrombin III: Implications for heparin efficacy. Proc Natl
Acad Sci USA 1989; 86 3619-23
15. Weitz JI, Hudoba M, Massel D, Maraganora JM, Hirsh J Clot-bound
thrombin is protected from inhibition by heparin-antithrombin III but is
susceptible to inactivation by antithrombin Ill-independent inhibitors J
Clin Invest 19901 86: 385-91.
16. Eisenberg PR Siegrl JE. .{bendschein DR, Miletich JP. Importance of fac-
tor Xa in determininu the procoagulant activity of whole-blood clots. J Clin
Invest 199-l: 9l: 1877-83.
17. Marciniali E. Factor-Xa lnactivation by antithrombin III: Evidence for bio-
logical stabilization of factor Xa by factor V-phospholipid complex. Br J
Haematol 197,i: 21: 391-400.
18. Miletich JP. Jackson CM, Majerus PW. Properties of the factor Xa binding
site on human platelets. J Biol Chem 1978; 253: 6908-16.
19 Teitel JM, Rosenberg RD. Protection of factor Xa from neutralization by
the heparin-antithrombin complex. J Clin Invest 1983; 71: 1383-91.
20 Lindhout T, Baruch D, Schoen P, Franssen J, Hemker HC. Thrombin
generation and inactivation in the presence of antithrombin III and heparin.
Biochemistry 1986; 25 : 5962-9.
2l.Ellis V, Scully MF, Kakkar W. The acceleration of the inhibition of
platelet prothrombinase complex by heparin. Biochem J 1986;233: 16l-5.
22. Banowcliffe TW, Havercroft SJ, Kemball-Cook G, Lindahl U The effect
of Ca2*, phospholipid, and factor V on the anti-(factor Xa) activity of
heparin and its high affinity oligosaccharides Biochem J 1987 ;243: 31-j
23. Schoen P, Lindhout T, Willems GM, Hemker HC Antithrombin III depen-
dent anti-protlrombinase activity of heparins of various molecular weight.
J Biol Chem 1989:264:10002-1.
24. Schoen P, Lindhout T. Flow and the inhibition of prothrombinase by
antithrombin III and heparin. Blood 1991; 78: Il8-24.
25 Billy D, Speijer H, Willems G, Hemker HC, Lindhout T. Prothrombin
activation by prothrombinase in a tubular flow reactor A kinetic study.
J Biol Chem 1995:2'70:1029-34.
26 Schoen P, Wielders S, Petitou M, Lindhout T. The effect of sulfation on the
anticoagulant and antithrombin Ill-binding properties of a heparin fraction
with 1ow affinity for antithrombin III. Thromb Res 1990; 5'7:415-23
27. Lindhout T, Govers-Riemslag JWP, van de Waarl P, Hemker HC, Rosing J.
Factor Va-factor Xa interaction Effects ofphospholipid vesicles of varying
composition. Biochemistry 1982; 21 : 5 49 4-502.
28 Levich VG. Physiochemical Hydrodynamics Englewood Cliffs, NJ, Pren-
tice-Hall, 1962,p75.
29. Atha DH, Lormeau JC, Petitou M, Rosenberg RD, Choay J. Contribution
of monosaccharide r sidues in heparin binding to antithrombin III.
Biochemishy 1985 : 24: 67 23-9.
30 Olson ST, BjUrk I, Sheffer R, Craig PA, Shore JD, Choay J. Role of the
antithrombin-binding pentasaccharide in heparin acceleration of anti-
thrombin-proteinase reactions. J Biol Chem 1992: 267 : 12528-38.
31. Schoen P, Lindhout T, Hemker HC. Ratios of anti-factor Xa to anti-
thrombin activities of heparins as determined in recalcified human plasma
Brit J Haematol 1992;81:255-62.
Received November 14,1994 Accepted after revision January 13, 1995
A manual for every physician who is faced with skin lesions in
daily practice. The malignant melanoma is increasing in incidence
worldwide like no other malignant tumor and continues toentail
high mortality. Therefore, arly recognition is of literally vital
importance. The authors have compiled a color atlas encompassing
the clinical symptoms, histopathology and differential diagnoses
of all the special forms of malignant melanoma, benign evi and
other pigmented skin lesions. At the head 0f every chapter adia-
gram is provided which represents an idealized cross-section
through the skin showing the clinical and histopathological appear-
ance 0f the individual skin lesions, A special chapter isdedicated
to dermatoscopy. Didactically clear photographs of clinical find-
ings and of histopathological specimens complete he visual mate-
rial.
Hijlzle .Kind Plewig .Burgdorf
Malignant Melanoma
Diagnosis and Differential Diagnosis
1993. 139 pages, 172 figures,
7 tables, cbd.
DM 148,00 / approx. US $ 99 00
ISBN 3-7945-1481-5
@ Schattauer
Distributor for United States and
Canada:
John Wiley & Sons, Inc.
Wley-Liss Division, 605 Third Avenue
New York, N.Y 101 58-00 l2ruSA
653
